Takeda Pharmaceutical’s soticlestat did not meet Phase 3 goals in Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy. But the pharma giant points to results on secondary ...

In children with Dravet syndrome, the researchers found significant mitochondrial dysfunction in their LCLs. These cells had lower energy production, with particular problems in mitochondrial ...

Dravet Syndrome impacts 1 in about every 15,700 infants in the U.S. Most cases are caused by a mutation of the SCN1A gene, which is important for proper brain cell function.

Children's Hospital of Philadelphia. "Researchers redefine the mechanisms of Dravet syndrome." ScienceDaily. ScienceDaily, 29 March 2022. <www.sciencedaily.com / releases / 2022 / 03 ...

Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

The Phase 1 trial is being conducted in Europe. Following successful completion of the Phase 1 trial, Bloom intends to initiate a Phase 2 study in patients with Dravet syndrome. More information ...

Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program. While studies for STK-001, now known as zorevunersen, had ...

A woman has completed a challenge to walk 5km a day during the month of May in order to raise funds and awareness of the rare condition she has. Lucy Murphy, 25, from Exeter, has Dravet Syndrome ...

Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers.

Dravet Syndrome is a rare, severe and lifelong form of epilepsy. There is very little awareness about it, and even less money being raised and going towards a cure.